A genetically engineered porcine model of pancreatic ductal adenocarcinoma captures the biological complexity of the human disease.

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with limited treatment options and poor patient outcomes. The lack of clinically relevant large animal models hinders the investigation of early disease mechanisms and translational therapeutic strategies. In this study, we present a genetically engineered porcine PDAC model involving pancreas-specific activation of latent KRASG12D alone (KC) or in combination with TP53R167H (KPC), developed in a midipig background. KC pigs predominantly developed progressive acinar-to-ductal metaplasia (ADM), whereas KPC pigs showed accelerated tumour progression, including PanINs, invasive carcinoma, perineural invasion, and early lymphatic dissemination. Histopathological and molecular analyses revealed pronounced intra- and inter-tumour heterogeneity, a complex stromal microenvironment, and expression of key PDAC markers. Tumours exhibited early alterations in oncogenic KRAS signalling, including increased dosage and differential expression of isoforms, together with dysregulation of tumour suppressor networks involving p16 and TP53 family members. Single-cell transcriptomics and flow cytometric analyses demonstrated an organised and functionally active immune landscape in early lesions, characterised by infiltrating effector and regulatory T-cell populations. Porcine pancreatic cancer cell lines (PoPaCa) were established from KC and KPC tumours, recapitulating key genetic and transcriptional features of the primary lesions. Exploratory drug screening demonstrated heterogeneous responses to clinically relevant and experimental compounds. Responses to gemcitabine and paclitaxel overlapped qualitatively with those observed in human PDAC cell lines, whereas pronounced sensitivity to the GPX4 inhibitor RSL3 and partial responsiveness to trametinib identified testable therapeutic phenotypes for further validation. Together, this genetically engineered porcine PDAC model captures early molecular, cellular, and microenvironmental features of pancreatic tumorigenesis and provides a translational platform to study disease initiation, tumour heterogeneity, immune interactions, and therapeutic response beyond the constraints of rodent models.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-17
DOI
https://doi.org/10.64898/2026.11.16.766135
Primary Topic
Pancreatic and Hepatic Oncology Research
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

A genetically engineered porcine model of pancreatic ductal adenocarcinoma captures the biological complexity of the human disease.

Alexander Rinke Carrapeiro, Katja Steiger, Yiran Zheng, Sandra Wiedenmann et al.
1 links
bioRxiv (Cold Spring Harbor Laboratory)
Pancreatic and Hepatic Oncology Research
preprint

A genetically engineered porcine model of pancreatic ductal adenocarcinoma captures the biological complexity of the human disease.

Alexander Rinke Carrapeiro, Katja Steiger, Yiran Zheng, Sandra Wiedenmann, Krzysztof Flisikowski, Daniela Kalla, Michael Walter Pfaffl, Christian Schneeweis, Rouzanna Istvánffy, Laura Beltrán Sangüesa, Alexander Kind, Christian Graetz, Thomas Winogrodzki, Angelika Schnieke, Tatiana Flisikowska, İhsan Ekin Demir, Gregers Jungersen, Dieter Saur, Roland M. Schmid, Evelína Šťastná, Matthias Meier, Bernard Klinger, Wei Liang, Annika Eckstein, Theresa Maria Pauli, Kexin Wang
preprint en

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with limited treatment options and poor patient outcomes. The lack of clinically relevant large animal models hinders the investigation of early disease mechanisms and translational therapeutic strategies. In this study, we present a genetically engineered porcine PDAC model involving pancreas-specific activation of latent KRASG12D alone (KC) or in combination with TP53R167H (KPC), developed in a midipig background. KC pigs predominantly developed progressive acinar-to-ductal metaplasia (ADM), whereas KPC pigs showed accelerated tumour progression, including PanINs, invasive carcinoma, perineural invasion, and early lymphatic dissemination. Histopathological and molecular analyses revealed pronounced intra- and inter-tumour heterogeneity, a complex stromal microenvironment, and expression of key PDAC markers. Tumours exhibited early alterations in oncogenic KRAS signalling, including increased dosage and differential expression of isoforms, together with dysregulation of tumour suppressor networks involving p16 and TP53 family members. Single-cell transcriptomics and flow cytometric analyses demonstrated an organised and functionally active immune landscape in early lesions, characterised by infiltrating effector and regulatory T-cell populations. Porcine pancreatic cancer cell lines (PoPaCa) were established from KC and KPC tumours, recapitulating key genetic and transcriptional features of the primary lesions. Exploratory drug screening demonstrated heterogeneous responses to clinically relevant and experimental compounds. Responses to gemcitabine and paclitaxel overlapped qualitatively with those observed in human PDAC cell lines, whereas pronounced sensitivity to the GPX4 inhibitor RSL3 and partial responsiveness to trametinib identified testable therapeutic phenotypes for further validation. Together, this genetically engineered porcine PDAC model captures early molecular, cellular, and microenvironmental features of pancreatic tumorigenesis and provides a translational platform to study disease initiation, tumour heterogeneity, immune interactions, and therapeutic response beyond the constraints of rodent models.

bioRxiv (Cold Spring Harbor Laboratory)
Statens Serum Institut (DK), Helmholtz Centre for Environmental Research (DE), Munich University of Applied Sciences (DE), German Cancer Research Center (DE), TUM Klinikum (DE), Helmholtz Zentrum München (DE), Life University (US), University of Life Sciences in Poznań (PL), Technical University of Munich (DE), Leipzig University (DE)
Deutsche Forschungsgemeinschaft
Good health and well-being
Pancreatic and Hepatic Oncology Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon